SALT LAKE CITY, Utah, Aug. 4 /PRNewswire/ -- LineaGen Research Corporation today announced that Michael S. Paul, Ph.D. has been promoted to President of the company. Dr. Paul will continue to hold the position of Chief Operating Officer. Stephen M. Prescott, M.D., who previously held the titles of President and Chief Executive Officer, will continue to serve as LineaGen's CEO.
Dr. Prescott said, "Michael embodies an exceptional combination of personal and professional excellence in both science and business, and I am extremely pleased to announce his promotion to President. He has contributed significantly to LineaGen's development and success since inception and has recently played an instrumental role in securing agreements with some of the most influential and respected businesses in our industry, including IBM and Amgen."
Michael S. Paul, Ph.D. joined LineaGen in 2002 as Chief Operating Officer and Vice President for Corporate Development. Prior to joining LineaGen, Michael worked for the start-up company Huntsman Biotechnology Corporation as V.P., Business Development and for the publicly traded biopharmaceutical company NPS Pharmaceuticals, Inc. as Director, Strategic Development. In these roles, he led multidisciplinary product development teams, formulated strategic development alternatives for management, and was responsible for the strategic management of corporate intellectual property.
Dr. Paul also interned at the University of Utah Technology Transfer Office where he participated in the marketing of University inventions to the pharmaceutical and biotechnology industry. Dr. Paul serves on the board of the Utah Life Science Association and AnzenBio. He is a Governor Appointee to the Steering Committee of the Utah Technology Industry Commission and is active in the Utah chapter of the Licensing Executive Society. Dr. Paul received his B.A. in Biology from Colby College and his Ph.D. degree in Biochemistry and Molecular Biology from the University of Utah. Dr. Paul is registered to practice before the United States Patent and Trademark Office.
LineaGen Research Corporation is a biotechnology research and licensing company that utilizes a powerful population genetics discovery platform to identify and validate biomarkers, coordinate clinical trials, and identify health-promoting and disease-causing genetic factors. LineaGen provides industry partners with breakthrough genetic research programs that leverage an extensive biosample repository coupled with detailed clinical data and decades of medical and genetic information from both population-based studies and studies on multigenerational families. LineaGen's key asset is its ability to provide commercial access to research using the Utah Population Database and Utah Genetic Reference Project.
Headquartered in Salt Lake City, Utah, LineaGen draws on a proven process for genetic discovery at the University of Utah that has led to the discovery of multiple disease-causing genes in cancer, heart disease, and neurological disorders. This history of success has been expanded to disease areas including autoimmune and inflammatory disorders, respiratory disease, metabolic disorders, central nervous system disorders, and age-related conditions. On the Net: http://www.LineaGen.org
President and COO
MacDougall Biomedical Communications
LineaGen Research Corporation